PV Therapeutic Area Head RBD / RDSanofiBridgewater, New Jersey, United States
PB0634 - A Phase 3, single-arm, multicenter, open-label, one-way crossover study to evaluate the efficacy and safety of fitusiran prophylaxis in people with severe hemophilia A or B, with or without inhibitors
Monday, June 26, 202318:30 – 19:30 ET
